The association between serum Sestrin2 and the risk of coronary heart disease in patients with type 2 diabetes mellitus

Abstract

Background Coronary heart disease (CHD) is one of the most common causes of morbidity and mortality in type 2 diabetes mellitus (T2DM). Oxidative stress is one of the important contributors to the pathogenesis of CHD. Sestrin2 is a stress-induced antioxidant protein that plays a important role in T2DM and CHD. However, the relationship between serum Sestrin2 levels and T2DM with CHD remains unclear. Aim This study aimed to investigate the relationship between serum Sestrin2 levels and CHD in patients with type 2 diabetes. Methods A total of 70 T2DM patients with CHD and 69 T2DM patients were enrolled in this study. Clinical features and metabolic indices were identified. Serum Sestrin2 was measured by ELISA. Results Serum Sestrin2 levels in T2DM-CHD groups were significantly lower compared with the T2DM group (11.17 (9.79, 13.14) ng/mL vs 9.46 (8.34, 10.91) ng/mL). Bivariate correlation analysis revealed that serum Sestrin2 levels were negatively correlated with age (r = − 0.256, P = 0.002), BMI (r = − 0.206, P = 0.015), FBG (r = − 0.261, P = 0.002) and Tyg index (r = − 0.207, P < 0.014). Binary logistic regression suggested that low serum Sestrin2 levels were related to the increased risk of T2DM-CHD (P < 0.05). In addition, the receiver operating characteristic analysis revealed that the area under the curve of Sestrin2 was 0.724 (95% CI 0.641–0.808, P < 0.001) to predict T2DM-CHD patients (P < 0.001). Conclusion The Sestrin2 levels were highly associated with CHD in diabetes patients. Serum Sestrin2 may be involved in the occurrence and development of diabetic with CHD.

Effect of the index of cardiac electrophysiological balance on major adverse cardiovascular events in patients with diabetes complicated with coronary heart disease

“… Tian et al (2022) discovered a strong correlation between serum Sestrin2 levels and coronary heart disease (CHD) in diabetic patients, implying that serum Sestrin2 may contribute to the development and progression of CHD in individuals with diabetes. This research highlighted a direct role in the association between diabetes mellitus (DM) complicated with CHD and major adverse cardiac events (MACE).…”

Sestrin2 in diabetes and diabetic complications

“…Also, plasma Sestrin2 levels were found to be increased in patients with coronary heart disease (CAD) and positively related to the severity of CAD ( 184 , 186 ). However, lower serum Setrin2 levels were indicated in patients with septic cardiomyopathy and in T2DM patients with CHD ( 126 , 185 ). Low Sestrin2 level was a risk factor for CHD in T2DM patients ( 126 ).…”

“…However, lower serum Setrin2 levels were indicated in patients with septic cardiomyopathy and in T2DM patients with CHD ( 126 , 185 ). Low Sestrin2 level was a risk factor for CHD in T2DM patients ( 126 ). The contradictory results concerning the beneficial or harmful effects of sestrin2 in cardiomyopathy and heart failure need to be further clarified.…”

“…PI3K/AKT signaling is related to the Hippo pathway and both of these pathways take part in the pathogenesis of DKD (158). Sestrin2 overexpression was found to alleviate renal damage via regulating Hippo pathway in DKD mice (125). Considering the interactions among Sestrin2 and multiple signaling pathways, Sestrin2 may be critically in involved in the development of DKD and thus may perform as a latent therapeutic target for DKD.…”

An update on the bridging factors connecting autophagy and Nrf2 antioxidant pathway

“…Sestrin2 has been proposed to be the therapeutic target for various diseases, such as cardiac diseases, respiratory diseases, and non-alcoholic fatty liver disease ( Ren D. et al, 2020 ; Sun et al, 2020 ; Wu D. et al, 2021 ). Sestrin2 has been reported to protect insulin-resistant cells by activating the AMPK pathway or upregulating the mTOR pathway ( Gong et al, 2021 ), thus promoting a beneficial effect on diabetes ( Tian et al, 2022 ).…”